Enasidenib is an innovative therapeutic drug that has significant therapeutic effects on a range of illnesses. It is an IDH2 inhibitor designed to improve patient outcomes in acute myeloid leukemia (AML), a cancer of the blood and bone marrow. Enasidenib Cas: 3446502-11-9 is an oral drug that received FDA approval in August 2017, making it the first-ever treatment for relapsed or refractory AML patients that targets the IDH2 enzyme.
Enasidenib Chemical Name:
Enasidenib is the generic name for AG-221. It is also known by its proposed International Nonproprietary Name (INN), Idhifa.
Enasidenib Molecular Formula:
The molecular formula of Enasidenib is C19H17FN6O3.
Enasidenib Formula Weight:
The formula weight of Enasidenib is 384.37 g/mol.
Enasidenib CAS No:
Enasidenib's CAS number is 3446502-11-9.
Keywords and Synonyms:
Top keywords for Enasidenib that are searched in Google include: Enasidenib, IDHIFA, AG-221, acute myeloid leukemia, AML, and Idhifa. Some synonyms for Enasidenib include Idhifa, AG-221, and Enasidenib mesylate.
Health Benefits of Enasidenib:
Enasidenib has been shown to improve health outcomes in patients with relapsed or refractory AML. Enasidenib Cas: 3446502-11-9 is used as a monotherapy for the treatment of AML patients that have IDH2 mutations, which occur in about 12% of patients with AML. Enasidenib targets the IDH2 enzyme, which is mutated in some people with AML, leading to increased production of an oncometabolite called 2-hydroxyglutarate (2-HG). Elevated levels of 2-HG can cause cancer cells to grow in an uncontrolled manner. By inhibiting the IDH2 enzyme, Enasidenib reduces the production of 2-HG, slowing the growth of AML cells.
Potential Effects of Enasidenib:
Enasidenib has the potential to improve the outcomes of patients with relapsed or refractory AML. In a clinical trial of Enasidenib monotherapy, 19% of patients achieved a complete remission, and 4% exhibited a complete remission with incomplete blood count recovery.
Enasidenib is an IDH2 inhibitor that targets the IDH2 enzyme in patients with AML. The IDH2 enzyme converts isocitrate to alpha-ketoglutarate (alpha-KG). The enzyme is mutated in some people with AML, leading to increased production of an oncometabolite called 2-HG. Elevated levels of 2-HG can cause cancer cells to grow in an uncontrolled manner. Enasidenib inhibits the mutated IDH2 enzyme, reducing the production of 2-HG, and slowing the growth of AML cells.
Safety of Enasidenib:
Enasidenib is generally safe for use in AML patients with IDH2 mutations. However, as with any medication, Enasidenib can cause side effects in some patients. Patients should be monitored for adverse reactions during Enasidenib treatment.
The most common side effects associated with Enasidenib treatment include nausea, vomiting, diarrhea, decreased appetite, constipation, fatigue, increased creatinine level, decreased potassium level, increased bilirubin level, and differentiation syndrome